Searchable abstracts of presentations at key conferences in obesity
Previous issue | Volume 4 | OU2024

Obesity Update 2024

London, UK
19 Jan 2024 - 19 Jan 2024

Card image cap
Obesity Update is the UK's leading conference for professionals working in the field of bariatrics.


Oral Communications

ob0004oc1 | Oral Communications | OU2024

Tier 3 Obesity Services in England - ongoing failure to meet need

Finer Nick , Seagar Sarah , Linda Parson , Cecilia Pyper

Provision of Tier 3 (T3) services as defined in NHS commissioning guidelines are integral to NICE obesity guidelines. Previous surveys have shown that people with obesity face a postcode lottery in accessing them. With the establishment of Integrated Care Boards (ICBs) now responsible for commissioning T3 services, we undertook a survey using Freedom of Information requests to all English ICBs in October 2023 asking for: a comprehensive outline of the T3 obesity care pathways;...

ob0004oc2 | Oral Communications | OU2024

Associations between weight loss pre-hip or pre-knee arthroplasty and peri- and post-operative outcomes

Gill Moneet , Lindsay Timothy , Llanera David , Tan Tricia , Liddle Alex , Izzi-Engbeaya Chioma

Obesity is an important modifiable risk factor for developing osteoarthritis. Arthroplasty improves mobility and quality of life in those with osteoarthritis. BMI thresholds are mandated by some commissioning bodies in the UK, leading to extended waiting times for arthroplasty. Obesity is associated with increased complications after arthroplasty. It is unknown if these risks can be mitigated by weight loss pre-operatively. Our systematic review and meta-analysis explores the ...

ob0004oc3 | Oral Communications | OU2024

Comparing non-invasive biomarkers of non-alcoholic steatohepatitis in obesity

Vincent Royce , Panunzi Simona , Mare Tracey , Luxton James , le Roux Carel , Angelini Giulia , Garcovich Matteo , Riccardi Laura , Pompili Maurizio , Mingrone Geltrude

Background: Approximately 15-25% of the world population has non-alcoholic fatty liver disease (NAFLD) and nearly quarter go on to develop non-alcoholic steatohepatitis (NASH). Obesity and T2DM are strong risk factors with prevalence of NAFLD rising to 90% in obesity and 60% in T2DM. Liver biopsy remains the gold standard in diagnosis and prognosis; nevertheless, it is expensive and invasive. The underlying fibrosis stage is key in determining clinical outcome...